DrugInformations.org

Adam Heller, Ph.D., a professor at the University of Texas in Austin who created the technology that led to the development of Abbott’s FreeStyle Blood Glucose Monitoring Systems® and FreeStyle Navigator® Continuous Glucose Monitoring System, today received the 2007 National Medal of Technology and Innovation from President George W. Bush in an award ceremony at the White House.

More: continued here

No Comments »

Ark Therapeutics Group plc (”Ark” or the “Company”) today announces that it has successfully achieved reimbursement from the UK NHS Business Services Authority for Neuropad®, an innovative diagnostic test to detect early stage peripheral autonomic neuropathy in the feet of diabetic patients. Neuropad® is the first product in a new diagnostic class to be available to the NHS on prescription.

More: continued here

No Comments »

UroToday.com - In the September 10, 2008 issue of the Journal of Clinical Oncology, Dr. Matthew Smith and his colleagues reported on the association of diabetes mellitus (DM) and death in men treated for prostate cancer (CaP) with radiotherapy and androgen deprivation therapy (ADT). The authors cited a meta-analysis whereby an inverse relationship between diabetes and CaP diagnosis was noted.

More: continued here

No Comments »

Managing a chronic disease like diabetes can be overwhelming, even frightening-especially if you’re among the 1.5 million Americans who are newly diagnosed each year. Now there’s sound, steadying advice written by the experts, so you can live well with diabetes, not just manage it. What to Expect When You Have Diabetes is a worthy companion amid the glut of questions. This go-to guide with a can-do approach makes understanding diabetes easier.

More: continued here

No Comments »

MyCareTeam, Inc., a leading vendor of Internet-based diabetes management software, has announced the release of the newest version of its flagship diabetes management software, MCT-Diabetes. In addition to tracking glucose readings, MCT-Diabetes now allows the user to track and store meals in a “Meal Log”, build an “Insulin Log” and use “TotalView”, a state-of-the-art charting tool.

More: continued here

No Comments »

PPD, Inc. (Nasdaq: PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application to the U.S. Food and Drug Administration for marketing approval of alogliptin (SYR-322) and ACTOS® (pioglitazone HCl) in a single tablet for the treatment of type 2 diabetes. “We are very pleased with Takeda’s progression of the development of alogliptin/ACTOS,” said Fred Eshelman, PPD’s chief executive officer.

More: continued here

No Comments »

The proposed NHS Constitution will affect all of us and it is vital that people living with diabetes have their say. The Constitution will shape the future of the NHS and we need you to get involved. Workshop for people affected by diabetes 8 October in London The workshop will give you the chance to tell the Department of Health what you think. It is open to people with diabetes, parents and carers.

More: continued here

No Comments »

Global drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3) today announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME? (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change.

More: continued here

No Comments »

The International Diabetes Federation announced that it is calling on groups and individuals worldwide to get involved in activities to raise awareness of diabetes in the 50 days leading up to World Diabetes Day on November 14. The theme for this year’s campaign is “Diabetes in Children and Adolescents.” Diabetes is one of the most common chronic diseases to affect children. It can strike children of any age, even toddlers and babies.

More: continued here

No Comments »

GI Dynamics, a medical device company pioneering the development of new approaches to treat obesity and metabolic disorders, today announced new data regarding the EndoBarrier?, its novel, noninvasive device currently in clinical trials to treat obesity and type 2 diabetes. New data from a multi-center, randomized clinical trial indicate that the EndoBarrier is a safe, noninvasive device with excellent short-term weight loss results in morbidly obese patients.

More: continued here

No Comments »